GHRS GH Research PLC IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1855129 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $11.39M | $10.57M | $8.96M | $7.85M | $8.21M | $8.40M | $9.76M | $8.66M |
| SG&A expense | $5.33M | $6.00M | $5.75M | $4.88M | $4.74M | $4.22M | $3.46M | $2.87M |
| Operating income | -$16.72M | -$16.57M | -$14.70M | -$12.73M | -$12.94M | -$12.62M | -$13.22M | -$11.53M |
| Interest expense | $90,000 | $21,000 | $174,000 | $178,000 | $179,000 | $181,000 | $178,000 | $179,000 |
| Pretax income | -$14.14M | -$14.02M | -$9.29M | -$10.81M | -$8.80M | -$12.11M | -$10.38M | -$7.67M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$14.14M | -$14.02M | -$9.29M | -$10.81M | -$8.80M | -$12.11M | -$10.38M | -$7.67M |
| EBITDA | -$16.63M | -$16.48M | -$14.62M | -$12.66M | -$12.87M | -$12.54M | -$13.14M | -$11.45M |
| EPS (basic) | — | -0.23 | -0.15 | -0.19 | — | -0.23 | -0.20 | -0.15 |
| EPS (diluted) | — | -0.23 | -0.15 | -0.19 | — | -0.23 | -0.20 | -0.15 |
| Balance sheet | ||||||||
| Cash & equivalents | $246.25M | $249.65M | $253.87M | $244.95M | $100.79M | $90.06M | $87.13M | $77.48M |
| Current assets | $285.98M | $294.79M | $293.88M | $294.67M | $154.22M | $154.95M | $152.91M | $160.48M |
| PP&E, netmay include right-of-use assets (IFRS) | $620,000 | $692,000 | $739,000 | $705,000 | $748,000 | $859,000 | $896,000 | $975,000 |
| Total assets | $288.23M | $302.02M | $313.43M | $320.45M | $188.27M | $199.61M | $206.98M | $217.58M |
| Current liabilities | $8.38M | $10.41M | $9.97M | $9.92M | $8.95M | $9.79M | $7.80M | $7.28M |
| Total liabilities | $8.53M | $10.62M | $10.25M | $10.24M | $9.32M | $10.24M | $8.30M | $7.84M |
| Shareholders' equity | $279.70M | $291.40M | $303.18M | $310.21M | $178.95M | $189.37M | $198.68M | $209.75M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.33M | -$13.68M | -$8.97M | -$8.57M | -$10.45M | -$12.31M | -$9.94M | -$9.60M |
| Capital expenditure | $19,000 | $39,000 | $59,000 | $4,000 | $25,000 | $4,000 | $8,000 | $12,000 |
| Free cash flow | -$12.35M | -$13.72M | -$9.03M | -$8.58M | -$10.47M | -$12.31M | -$9.94M | -$9.61M |
| Investing cash flow | $8.84M | $9.78M | $15.71M | $11.84M | $21.33M | $15.28M | $19.73M | $8.79M |
| Financing cash flow | -$68,000 | -$66,000 | -$1.07M | $140.86M | -$59,000 | -$60,000 | -$114,000 | -$71,000 |
| Depreciation & amortization | $88,000 | $89,000 | $82,000 | $76,000 | $78,000 | $79,000 | $78,000 | $80,000 |
| Stock-based compensation | $2.66M | $2.30M | $1.90M | $1.64M | $759,000 | $300,000 | -$100,000 | $277,000 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.